One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that has plenty of competition. The human Fc receptor ...

Demand for psychedelics-assisted psychotherapy is increasing in Switzerland, but patients still have to wait up to a year.

When it came to being indulgent at last week’s Masters Champions Dinner, Zach Johnson didn’t hesitate. Calling into Colt Knost’s SiriusXM PGA Tour Radio show, “Gravy and the Sleeze,” Johnson provided ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in Ken Fisher’s portfolio. Trump’s “stupid” tariffs will fail ...

Johnson & Johnson has shifted its generative AI strategy away from broad experimentation across the healthcare conglomerate to a more focused approach. Chief Information Officer Jim Swanson said ...

Johnson & Johnson (NYSE:JNJ) Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning ...